{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:15:55Z","timestamp":1773296155546,"version":"3.50.1"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases\/NIH","doi-asserted-by":"crossref","award":["R21-AI126582"],"award-info":[{"award-number":["R21-AI126582"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases\/NIH","doi-asserted-by":"crossref","award":["U19-AI123862"],"award-info":[{"award-number":["U19-AI123862"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.coviro.2016.09.004","type":"journal-article","created":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T16:36:07Z","timestamp":1474302967000},"page":"55-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Viral evasion and challenges of hepatitis C virus vaccine development"],"prefix":"10.1016","volume":"20","author":[{"given":"Brian G","family":"Pierce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Yong","family":"Keck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven KH","family":"Foung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2016.09.004_bib0495","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.09.004_bib0500","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/cid\/ciw111","article-title":"Rising mortality associated with hepatitis C virus in the United States, 2003\u20132013","volume":"62","author":"Ly","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coviro.2016.09.004_bib0505","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.09.004_bib0510","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.coi.2015.06.010","article-title":"Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?","volume":"35","author":"Walker","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0515","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2016.1194759","article-title":"Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies","author":"Fauvelle","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.coviro.2016.09.004_bib0520","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C. virus drug resistance-associated substitutions: state of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.09.004_bib0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2016.03.022","article-title":"High mortality during direct acting antiviral therapy for hepatitis C patients with Child's C cirrhosis: results of the Irish Early Access Programme","author":"Gray","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0530","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1126\/science.aad1302","article-title":"MEDICINE. Global control of hepatitis C virus","volume":"349","author":"Cox","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.09.004_bib0535","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2014.00550","article-title":"The humoral immune response to HCV: understanding is key to vaccine development","volume":"5","author":"Cashman","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0540","first-page":"31","article-title":"Current and future prophylactic vaccines for hepatitis C virus","author":"Dunlop","year":"2015","journal-title":"Vaccine Dev Therapy"},{"key":"10.1016\/j.coviro.2016.09.004_bib0545","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1128\/JVI.02547-07","article-title":"Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production","volume":"82","author":"Saito","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0550","doi-asserted-by":"crossref","first-page":"13994","DOI":"10.1038\/srep13994","article-title":"Amino acid polymorphisms in hepatitis C virus core affect infectious virus production and major histocompatibility complex class I molecule expression","volume":"5","author":"Tasaka-Fujita","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2016.09.004_bib0555","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hep.28108","article-title":"Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activity","volume":"62","author":"Kachko","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.09.004_bib0560","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1128\/JVI.06492-11","article-title":"Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization","volume":"86","author":"Tarr","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0565","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/JVI.01941-12","article-title":"Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein","volume":"87","author":"Keck","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0570","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1128\/JVI.02458-15","article-title":"Antibody response to hypervariable region 1 interferes with broadly neutralizing antibodies to hepatitis C virus","volume":"90","author":"Keck","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0575","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.09.004_bib0580","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.09.004_sbref0585","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.gastro.2006.12.008","article-title":"Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo","volume":"132","author":"von Hahn","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2016.09.004_bib0590","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.3390\/v7072809","article-title":"Genetic diversity underlying the envelope glycoproteins of hepatitis C virus: structural and functional consequences and the implications for vaccine design","volume":"7","author":"Tarr","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2016.09.004_bib0595","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","article-title":"Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein","volume":"79","author":"Owsianka","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0600","doi-asserted-by":"crossref","first-page":"12473","DOI":"10.1128\/JVI.01138-09","article-title":"Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus","volume":"83","author":"Broering","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0605","doi-asserted-by":"crossref","first-page":"10584","DOI":"10.1128\/JVI.01402-14","article-title":"Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors","volume":"88","author":"Lavie","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0610","doi-asserted-by":"crossref","first-page":"15394","DOI":"10.1073\/pnas.93.26.15394","article-title":"Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein","volume":"93","author":"Farci","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.09.004_bib0615","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.antiviral.2014.02.013","article-title":"The past, present and future of neutralizing antibodies for hepatitis C virus","volume":"105","author":"Ball","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.coviro.2016.09.004_bib0620","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1128\/JVI.74.22.10407-10416.2000","article-title":"Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes","volume":"74","author":"Hadlock","year":"2000","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0625","doi-asserted-by":"crossref","first-page":"16269","DOI":"10.1073\/pnas.0705522104","article-title":"Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus","volume":"104","author":"Johansson","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.09.004_sbref0630","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nm1698","article-title":"Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge","volume":"14","author":"Law","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2016.09.004_bib0635","doi-asserted-by":"crossref","first-page":"e1002653","DOI":"10.1371\/journal.ppat.1002653","article-title":"Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate","volume":"8","author":"Keck","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.09.004_bib0640","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.21088","article-title":"Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33","volume":"43","author":"Tarr","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.09.004_bib0645","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1128\/JVI.00586-11","article-title":"Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step","volume":"85","author":"Sabo","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0650","doi-asserted-by":"crossref","first-page":"12245","DOI":"10.1128\/JVI.02070-15","article-title":"Monoclonal antibodies directed toward the hepatitis c virus glycoprotein E2 detect antigenic differences modulated by the N-terminal hypervariable region 1 (HVR1), HVR2, and intergenotypic variable region","volume":"89","author":"Alhammad","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_sbref0655","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.26430","article-title":"An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission","volume":"58","author":"Tarr","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.09.004_bib0660","doi-asserted-by":"crossref","first-page":"6205","DOI":"10.1073\/pnas.1114927109","article-title":"Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus","volume":"109","author":"Giang","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.09.004_bib0665","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1128\/JVI.01872-07","article-title":"Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus","volume":"82","author":"Meunier","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0670","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1126\/science.282.5390.938","article-title":"Binding of hepatitis C virus to CD81","volume":"282","author":"Pileri","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.09.004_bib0675","doi-asserted-by":"crossref","first-page":"41624","DOI":"10.1074\/jbc.M305289200","article-title":"Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor","volume":"278","author":"Bartosch","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2016.09.004_bib0680","doi-asserted-by":"crossref","first-page":"13199","DOI":"10.1128\/JVI.79.21.13199-13208.2005","article-title":"Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2","volume":"79","author":"Keck","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0685","doi-asserted-by":"crossref","first-page":"9224","DOI":"10.1128\/JVI.78.17.9224-9232.2004","article-title":"Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions","volume":"78","author":"Keck","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0690","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1099\/vir.0.83386-0","article-title":"Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein","volume":"89","author":"Owsianka","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0695","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1128\/JVI.02475-07","article-title":"Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies","volume":"82","author":"Keck","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0700","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1099\/vir.0.83065-0","article-title":"Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33","volume":"88","author":"Tarr","year":"2007","journal-title":"J Gen Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0705","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.jmb.2015.06.012","article-title":"Structure of hepatitis C virus envelope glycoprotein E1 antigenic site 314\u2013324 in complex with antibody IGH526","volume":"427","author":"Kong","year":"2015","journal-title":"J Mol Biol"},{"key":"10.1016\/j.coviro.2016.09.004_sbref0710","doi-asserted-by":"crossref","first-page":"9499","DOI":"10.1073\/pnas.1202924109","article-title":"Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1","volume":"109","author":"Kong","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.09.004_bib0715","doi-asserted-by":"crossref","first-page":"13085","DOI":"10.1128\/JVI.01939-12","article-title":"Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33","volume":"86","author":"Kong","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0720","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1128\/JVI.02190-14","article-title":"Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies","volume":"89","author":"Meola","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0725","doi-asserted-by":"crossref","first-page":"10117","DOI":"10.1074\/jbc.M115.643528","article-title":"Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody","volume":"290","author":"Li","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2016.09.004_bib0730","doi-asserted-by":"crossref","first-page":"12923","DOI":"10.1128\/JVI.02052-12","article-title":"Toward a hepatitis C virus vaccine: the structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody","volume":"86","author":"Potter","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0735","doi-asserted-by":"crossref","first-page":"e1003364","DOI":"10.1371\/journal.ppat.1003364","article-title":"Structural basis of HCV neutralization by human monoclonal antibodies resistant to viral neutralization escape","volume":"9","author":"Krey","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.09.004_bib0740","doi-asserted-by":"crossref","first-page":"7418","DOI":"10.1073\/pnas.1305306110","article-title":"Structural evidence for a bifurcated mode of action in the antibody-mediated neutralization of hepatitis C virus","volume":"110","author":"Deng","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.09.004_bib0745","doi-asserted-by":"crossref","first-page":"10690","DOI":"10.1073\/pnas.1411317111","article-title":"Discrete conformations of epitope II on the hepatitis C virus E2 protein for antibody-mediated neutralization and nonneutralization","volume":"111","author":"Deng","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.09.004_sbref0750","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1126\/science.1243876","article-title":"Hepatitis C virus E2 envelope glycoprotein core structure","volume":"342","author":"Kong","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.09.004_sbref0755","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature13117","article-title":"Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2","volume":"509","author":"Khan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.09.004_bib0760","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/j.jmb.2013.02.025","article-title":"Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies","volume":"425","author":"Pantua","year":"2013","journal-title":"J Mol Biol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0765","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.drudis.2014.08.011","article-title":"HCV E2 core structures and mAbs: something is still missing","volume":"19","author":"Castelli","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.coviro.2016.09.004_bib0770","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coviro.2015.02.004","article-title":"HCV glycoprotein structures: what to expect from the unexpected","volume":"12","author":"Khan","year":"2015","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2016.09.004_sbref0775","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1128\/JVI.00248-09","article-title":"Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity","volume":"83","author":"Keck","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0780","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1084\/jem.20090766","article-title":"Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation","volume":"207","author":"Fafi-Kremer","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.coviro.2016.09.004_bib0785","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/j.gastro.2012.04.006","article-title":"Mutations that alter use of hepatitis C virus cell entry factors mediate escape from neutralizing antibodies","volume":"143","author":"Fofana","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coviro.2016.09.004_bib0790","doi-asserted-by":"crossref","first-page":"19450","DOI":"10.1073\/pnas.0809879105","article-title":"In vitro selection of a neutralization-resistant hepatitis C virus escape mutant","volume":"105","author":"Gal-Tanamy","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.09.004_bib0795","doi-asserted-by":"crossref","first-page":"10451","DOI":"10.1128\/JVI.05259-11","article-title":"Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations","volume":"85","author":"Keck","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0800","doi-asserted-by":"crossref","first-page":"e1004297","DOI":"10.1371\/journal.ppat.1004297","article-title":"Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412\u2013423","volume":"10","author":"Keck","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.09.004_sbref0805","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/ajt.12083","article-title":"Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study","volume":"13","author":"Chung","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.coviro.2016.09.004_bib0810","doi-asserted-by":"crossref","first-page":"e100325","DOI":"10.1371\/journal.pone.0100325","article-title":"High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody","volume":"9","author":"Babcock","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coviro.2016.09.004_bib0815","doi-asserted-by":"crossref","first-page":"e1002895","DOI":"10.1371\/journal.ppat.1002895","article-title":"Human monoclonal antibody HCV1 effectively prevents treats HCV infection in chimpanzees","volume":"8","author":"Morin","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.09.004_bib0820","doi-asserted-by":"crossref","first-page":"8072","DOI":"10.1128\/JVI.00459-07","article-title":"Hepatitis C virus envelope glycoprotein E2 glycans modulate entry CD81 binding, and neutralization","volume":"81","author":"Falkowska","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0825","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1128\/JVI.00127-07","article-title":"The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein","volume":"81","author":"Helle","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0830","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.coviro.2015.04.001","article-title":"Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design","volume":"11","author":"Kong","year":"2015","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0835","doi-asserted-by":"crossref","first-page":"254ra129","DOI":"10.1126\/scitranslmed.3009512","article-title":"Broadly neutralizing antibodies abrogate established hepatitis C virus infection","volume":"6","author":"de Jong","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coviro.2016.09.004_sbref0840","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1172\/JCI78794","article-title":"Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance","volume":"125","author":"Bailey","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coviro.2016.09.004_sbref0845","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1128\/JVI.02700-15","article-title":"A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance","volume":"90","author":"Urbanowicz","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0850","doi-asserted-by":"crossref","first-page":"35631","DOI":"10.1074\/jbc.M112.382341","article-title":"Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion","volume":"287","author":"Guan","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coviro.2016.09.004_sbref0855","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2015-310300","article-title":"HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice","author":"Prentoe","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.coviro.2016.09.004_bib0860","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1016\/j.vaccine.2004.02.002","article-title":"A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers","volume":"22","author":"Leroux-Roels","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2016.09.004_bib0865","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1365-2893.2008.01058.x","article-title":"Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial","volume":"16","author":"Alvarez-Lajonchere","year":"2009","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.coviro.2016.09.004_bib0870","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/jvh.12163","article-title":"HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNalpha2a and Ribavirin: a randomized controlled trial","volume":"21","author":"Colombatto","year":"2014","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.coviro.2016.09.004_bib0875","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1016\/j.vaccine.2010.06.084","article-title":"Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults","volume":"28","author":"Frey","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coviro.2016.09.004_bib0880","doi-asserted-by":"crossref","first-page":"14278","DOI":"10.1128\/JVI.01911-14","article-title":"Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization","volume":"88","author":"Wong","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0885","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nm1353","article-title":"A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees","volume":"12","author":"Folgori","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2016.09.004_bib0890","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/hep.28294","article-title":"Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans","volume":"63","author":"Kelly","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.coviro.2016.09.004_bib0895","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.1073\/pnas.0702162104","article-title":"Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees","volume":"104","author":"Elmowalid","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coviro.2016.09.004_bib0900","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nature12966","article-title":"Proof of principle for epitope-focused vaccine design","volume":"507","author":"Correia","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coviro.2016.09.004_bib0905","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.09.004_bib0910","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.09.004_bib0915","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2016.09.004_bib0920","doi-asserted-by":"crossref","first-page":"10459","DOI":"10.1128\/JVI.01584-14","article-title":"Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex","volume":"88","author":"Ruwona","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0925","article-title":"N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses","author":"Ren","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.coviro.2016.09.004_bib0930","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1128\/JVI.02397-15","article-title":"Generation and characterization of monoclonal antibodies against a cyclic variant of hepatitis C virus E2 epitope 412\u2013422","volume":"90","author":"Sandomenico","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_sbref0935","doi-asserted-by":"crossref","first-page":"12501","DOI":"10.1038\/srep12501","article-title":"Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding","volume":"5","author":"He","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.coviro.2016.09.004_bib0940","doi-asserted-by":"crossref","first-page":"10333","DOI":"10.1128\/JVI.00991-15","article-title":"Hepatitis C virus envelope glycoprotein E1 forms trimers at the surface of the virion","volume":"89","author":"Falson","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0945","doi-asserted-by":"crossref","first-page":"e1003618","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.coviro.2016.09.004_bib0950","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1126\/science.1245625","article-title":"Crystal structure of a soluble cleaved HIV-1 envelope trimer","volume":"342","author":"Julien","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.coviro.2016.09.004_bib0955","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.cell.2015.05.007","article-title":"Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors","volume":"161","author":"Zhou","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.coviro.2016.09.004_bib0960","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1101\/gr.849004","article-title":"WebLogo: a sequence logo generator","volume":"14","author":"Crooks","year":"2004","journal-title":"Genome Res"},{"key":"10.1016\/j.coviro.2016.09.004_bib0965","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/bioinformatics\/bth485","article-title":"The Los Alamos hepatitis C sequence database","volume":"21","author":"Kuiken","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.coviro.2016.09.004_bib0970","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/B978-0-12-381270-4.00019-6","article-title":"ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules","volume":"487","author":"Leaver-Fay","year":"2011","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0975","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fmicb.2014.00329","article-title":"Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies","volume":"5","author":"Drummer","year":"2014","journal-title":"Front Microbiol"},{"key":"10.1016\/j.coviro.2016.09.004_bib0980","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1128\/JVI.02837-15","article-title":"A hepatitis C virus envelope polymorphism confers resistance to neutralization by polyclonal sera and broadly neutralizing monoclonal antibodies","volume":"90","author":"Wasilewski","year":"2016","journal-title":"J Virol"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716301262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625716301262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,8]],"date-time":"2018-09-08T04:59:36Z","timestamp":1536382776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625716301262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":98,"alternative-id":["S1879625716301262"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2016.09.004","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral evasion and challenges of hepatitis C virus vaccine development","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2016.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}